Nobody puts cancer in a corner!

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

This retrospective study included 64 patients with LMD, with primary cancers represented in the diagnosis-specific Graded Prognostic Assessment (DS-GPA) at a single institution over 5 years.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Telisotuzumab Vedotin Earns FDA Accelerated Approval in c-MET+ NSCLC

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

With this decision, telisotuzumab vedotin is the first and only available therapy for this NSCLC subtype.

Russ Conroy

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Data from the phase 2 LUMINOSITY study support the FDA approval of telisotuzumab vedotin in this non–small cell lung cancer population.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

FDA Approves Belzutifan in Adult/Pediatric Pheochromocytoma and Paraganglioma

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.

Tim Cortese;Ariana Pelosci

Loncastuximab Tesirine Combo Demonstrates Early Efficacy in R/R DLBCL

Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.

Roman Fabbricatore

Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease

The safety profile of loncastuximab tesirine plus glofitamab was consistent with the known profiles of the individual agents.

Related Content

Meghana Kesireddy, MBBS;Rosalyn Marar, MD;Kaeli Samson, MA, MPH;Nicole A. Shonka, MD

May 15th 2025

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

This retrospective study included 64 patients with LMD, with primary cancers represented in the diagnosis-specific Graded Prognostic Assessment (DS-GPA) at a single institution over 5 years.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Telisotuzumab Vedotin Earns FDA Accelerated Approval in c-MET+ NSCLC

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Russ Conroy

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Data from the phase 2 LUMINOSITY study support the FDA approval of telisotuzumab vedotin in this non–small cell lung cancer population.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

FDA Approves Belzutifan in Adult/Pediatric Pheochromocytoma and Paraganglioma

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Tim Cortese;Ariana Pelosci

Loncastuximab Tesirine Combo Demonstrates Early Efficacy in R/R DLBCL

Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.

Roman Fabbricatore